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REVIEW
Chronic non-cancer pain: Focus on once-daily 
tramadol formulations
Abstract: Despite progress in pain management, chronic non-cancer pain (CNCP) represents 
still a clinical challenge. The efﬁ  cacy and safety proﬁ  le of tramadol make it suitable as a long-
term treatment in a variety of CNCP conditions. New once-daily (OD) formulations of tramadol 
have been marketed in various countries, in order to offer the advantage of a reduced dosing 
regimen and to improve patients’ compliance. This review focuses on the technology, pharma-
cology, clinical efﬁ  cacy, and safety of different once-daily tramadol formulations. Hydrophilic 
vs hydrophobic matrix systems and newer technologies used in once-daily formulations to 
control drug delivery are discussed. Three randomized controlled trials (RCTs) established OD 
tramadol analgesic efﬁ  cacy to be superior to that of placebo for pain management and functional 
improvement in patients with osteoarthritis. Three RCTs demonstrated similar rates of efﬁ  cacy 
between OD tramadol and immediate-release (IR) or sustained-release (SR) formulations, with 
a better adverse events proﬁ  le. An open trial on long term tolerability showed that OD tramadol 
is generally safe in rheumatological pain treatment.
Keywords: tramadol, once-daily, pharmacokinetics, sustained-release, chronic non-cancer 
pain, formulations
Introduction
Despite progress in pain management, chronic pain remains a major problem in most 
of countries. Chronic pain was once deﬁ  ned as pain that extends 3 or 6 months beyond 
onset or beyond the expected period of healing. “Chronic nonmalignant pain” is a 
subtype of chronic pain, which refers to persistent pain not associated with cancer. 
As such pain may last for many years, some consider use of term “nonmalignant” 
inappropriate, and prefer to speak about “chronic noncancer pain” (CNCP). CNCP 
is a problem of epidemic proportions. About 50 million of the estimated 75 million 
Americans who live with “serious pain” suffer from chronic pain, substantially 
reducing their quality of life. Many have been living with their pain for more than 
5 years and experience pain almost 6 days a week. According to the Nuprin Pain 
Report, 20.8 millions of Americans experienced pain at least 101 days in the year 
preceding the survey. (Taylor 1985) CNCP can affect virtually any body system or 
region, and pain severity ranges from mild to excruciating. It includes chronic pain 
of a nociceptive or neuropathic nature with variable inﬂ  uence by psychological and 
socioenvironmental factors.
Musculoskeletal conditions such as low back pain and osteoarthritis (OA) repre-
sent a leading cause of disability among individuals of working age. According to a 
recent report from the centers for disease control (CDC), the estimated prevalence 
of arthritis and chronic joint symptoms among adults in the United States was 33%, 
representing approximately 69.9 million adults in 2001. The socioeconomic burden 
also is signiﬁ  cant, with chronic pain estimated to cost about 50 billion dollars annually 
in medical expenses. However, when considering the reduced work productivity, due 
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to 36 million lost work days annually, the total cost rose to 
about 90 billion dollars (CDC 2006).
Despite progress in our knowledge of the pathophysiology 
of pain and OA, the management of chronic non-cancer pain 
continues to challenge physicians. Contemporary standard 
pharmacological care for the treatment of CNCP includes 
the use of opioid medications. The aim of opioid treatment 
should be to relieve pain and improve functional capacity and 
quality of life. Evidence from multiple randomized controlled 
trials indicates that opioids can relieve pain in a variety of 
chronic pain syndromes (Kalso et al 2003).
Tramadol is a synthetic, centrally acting analgesic that has 
been widely used for chronic pain management. Its analge-
sic effect results from two different pharmacologic actions. 
Tramadol displays a weak agonistic effect at the µ- and δ-
opioid receptors and a weaker afﬁ  nity for κ-opioid receptors 
(Grond et al 2004). However, tramadol-induced analgesia is 
only partly antagonised by the opioid antagonist naloxone, 
whereas both the α2-adrenoreceptor antagonist, yohimbine 
(Desmeules et al 1996), and the selective 5-HT3 receptor 
antagonist, ondansetron (De Witte et al 2001), reduced its 
analgesic effect. In fact, tramadol acts also on the descending 
inhibitory pathways by inhibiting monoamine (noradrenaline 
and serotonin) re-uptake.
Tramadol is formulated as a racemic mixture consisting 
of two enantiomers. The main activity of enantiomer(–) is 
the inhibition of the neuronal re-uptake of noradrenaline, 
whereas enantiomer(+) both interacts with µ-opioid receptors 
and increases serotonin synaptic concentrations by blocking 
serotonin re-uptake (Grond et al 2004).
The efﬁ  cacy and safety proﬁ  le of tramadol make it suit-
able as a long-term treatment in a variety of CNCP condi-
tions. In osteoarthritis patients (double-blind study), pain 
relief was superior with oral tramadol 300 mg than with oral 
dextropropoxyphene 300 mg (Jensen et al 1994). Similarly, 
in a double-blind crossover trial, tramadol 200 mg was 
shown to be more effective than pentazocine 150 mg (Bird 
et al 1995. No signiﬁ  cant differences were observed in pain 
relief between tramadol and diclofenac (Pavelka et al 1998) 
and paracetamol/codeine combination (Rauck et al 1994). 
In the treatment of severe pain from osteoarthritis, similar 
pain relief was achieved with both long-acting tramadol and 
dihydrocodeine with NSAID's, but tramadol interfered less 
with intestinal function (Wilder-Smith et al 2001).
Tramadol is classiﬁ  ed as a “step II” opioid analgesic in the 
World Health Organization (WHO) pain treatment ladder. The 
American Pain Society guidelines recommend tramadol in 
any phase of osteoarthritis as single therapy or in combination 
with acetaminophen or non-steroidal anti-inﬂ  ammatory drugs 
(NSAIDs). (APS 2002) Similarly, the American College 
of Rheumatology (ACR) guidelines on the management of 
osteoarthritis recommend tramadol in patients for whom 
acetaminophen, NSAIDs, and cyclo-oxygenase (COX)-2 
inhibitors are no longer effective (ACR 2000).
The use of stronger opioid analgesics for long term 
management of chronic non-cancer pain is now an accepted, 
although still a controversial medical practice. According 
to recent recommendations on the use of opioids in osteo-
arthritis, patients for whom NSAIDs are contraindicated, or 
for whom combined acetaminophen, tramadol, and NSAID 
therapy is ineffective, may be started on low-dose opioids 
and titrated as needed and tolerated (Goodwin et al 2005). 
In particular oxycodone and morphine seem to be effective 
in both neuropathic and musculoskeletal pain conditions 
(Kalso et al 2004). Strong opioids have a role in the treat-
ment of low back pain when other treatments have failed. 
They should be prescribed as part of a multimodal treatment 
plan, with the aim of relieve pain and facilitate rehabilitation 
(Kalso et al. 2005).
Tramadol has been available for pain treatment in 
Germany since 1977. The immediate release (IR) formula-
tions were introduced in the UK (1994), in the US (1995) 
and then in many other countries. The short half-life of IR 
tramadol requires dosing every 6 hours in order to main-
tain optimal analgesia. Sustained release formulations are 
recommended in chronic pain treatment to avoid the “peak 
and valley” phenomena in drug serum concentration and 
to maintain a stable level of analgesia. The introduction 
of twice-daily sustained-release (SR) formulations, which 
provide stable plasma concentrations when administrated at 
12-hour intervals, represented the ﬁ  rst goal of pharmaceutical 
research. There is an inverse relationship between number of 
daily doses and rate of compliance to treatment (Claxon et al 
2001). High-frequency dosing regimens can result in a lack 
of compliance, and subsequent inappropriate plasma drug 
concentrations and analgesia, thus they are not suitable for 
patients in chronic treatment. Extended-release formulations 
have been shown to provide the patient with better symptom 
control (Richter et al 2003).
Several studies have demonstrated the effectiveness of 
SR tramadol in the treatment of chronic pain of nonmalignant 
origin, with fewer adverse effect than the standard formula-
tion and better patient compliance during treatment (Sorge 
et al 1997; Frank et al 1999).
Once-daily (OD), sustained-release formulations of trama-
dol, have been recently marketed in various countries, with the Therapeutics and Clinical Risk Management 2007:3(5) 821
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aim of providing continuous drug delivery and corresponding 
analgesic efﬁ  cacy over 24 hours. The expected advantages are 
the reduction of plasma drugs peaks responsible of adverse 
events and the improvement of patient compliance with a once-
daily dosing regimen (Klotz et al 2003; Malonne et al 2003).
This review focuses on the technology, pharmacology, 
clinical efﬁ  cacy, and safety of different once-daily tramadol 
formulations.
Once-daily tramadol: different 
formulations
Tramadol is available in various pharmaceutical forms. 
Immediate-release (IR) formulations are capsules, soluble 
tablets, drops and suppositories. IR formulations normally 
require four to six times daily administrations, because tra-
madol is a freely water-soluble drug and its half-life is about 
5.5 hours (Scott et al 2000).
Several sustained-release (SR) formulations of tramadol 
have been developed for twice daily administration (capsules 
and tablets). SR capsules contain multiple pellets of 1mm 
diameter (from 90 to 370, depending on dosage) consisting 
of a neutral core layered with tramadol and a membrane that 
controls the release (Grond et al 2004). SR tablets instead are 
based on a matrix system in which tramadol is distributed, 
which on contact with the gastrointestinal ﬂ  uid is gradu-
ally swelled and forms a retarding gel layer. Tramadol SR 
capsules had identical bioavailability to tramadol immediate-
release capsules with lower peak concentrations and less 
ﬂ  uctuation in plasma concentrations (Keating 2006).
In order to reduce the frequency of administration and 
to improve patient compliance, once-daily formulations 
have been developed. The most commonly used method of 
modulating the drug release is to include it in a matrix sys-
tem. A wide array of polymers has been employed as drug 
retarding agents.
In Europe, an hydrophilic OD tramadol formulation is 
produced by SMB and THERABEL GN Pharma. Hydrophilic 
polymer matrix systems are widely used in oral controlled 
drug delivery. Hydroxypropyl methylcellulose (HPMC) 
is commonly used in these systems (Hogan et al 1989). 
The hydration rate of HPMC increases with an increase 
in the hydroxypropyl content. As tramadol is a highly 
water-soluble drug, when a hydrophilic matrix is used, its 
efﬁ  cacy is restricted due to rapid diffusion of the dissolved 
drug through the hydrophilic gel network. In an attempt to 
prolong the release of drug, the concentration of HPMC was 
increased. However the hydrophilic matrix system could 
not control the release of tramadol for more than 14 hours 
(Tiwari et al 2003).
For such drugs with high water solubility, hydrophobic 
polymers could represent more suitable matrixing agents 
for obtaining once-daily sustained-release dosage forms. An 
OD tramadol formulation based on a hydrophobic matrix is 
marketed by Napp Labs, Mundipharma, Zambon and MEDA. 
When a hydrophobic matrix system using hydrogenated 
castor oil (HCO) was investigated, the tramadol release rate 
was slower compared with the hydrophilic matrix system. 
Ethyl cellulose coating has been used, as a release retardant 
polymer, for hydrophobic matrix tablets. By comparison, 
combination of hydrophilic and hydrophobic polymers failed 
to prolong the drug release beyond 12 hours. In conclusion, 
the hydrophobic matrix seems to be a better system for 
once-daily formulations of a highly water-soluble drug like 
tramadol hydrochloride (Tiwari et al 2003).
Recently, a novel technology has been used by Labopharm 
Inc. (Canada) to obtain a new once-daily formulation, which 
permits controlled drug release over 24 hours (Mongin et al 
2004). Contramid® is a patented, Labopharm’s proprietary 
advanced controlled-release drug delivery technology that 
uses cross-linked high-amylose starch (CLHAS) molecules 
as matrixing agents, for oral administration of solid dosage 
medications. (Ispas-Szabo et al 2000) Such CLHAS is pre-
pared by (a) cross-linking and chemical modiﬁ  cation of high 
amylose starch, (b) gelatinization, and (c) drying to obtain a 
powder capable of being used as a controlled release excipient. 
Following ingestion, gastric ﬂ  uids transform the surface of the 
Contramid® into a semi-permeable membrane that stabilizes 
rapidly. This self-forming membrane, which does not begin 
to erode until it reaches the colon, regulates the release of the 
active drug. Contramid® technology can be applied success-
fully to a wide variety of active ingredients. The Tramadol 
Contramid® formulation is already distributed in Europe and 
is pending of FDA approval in USA. Labopharm’s New Drug 
Submission (NDS) for OD Tramadol Contramid® has been 
accepted for review by the Therapeutic Products Directorate 
of Health Canada (Labopharm 2006).
Moreover, there is another tablet formulation manu-
factured by Biovail Corporation (once-daily Ultram® ER) 
that uses the innovative Smartcoat TM technology to gain 
a graduated release of the active drug. This is the only OD 
tramadol currently approved in USA (Biovail 2006).
In September 2006, Cipher Pharmaceuticals Inc. (TSX: 
DND) announced that the Company’s New Drug Application 
(NDA) for CIP-TRAMADOL ER, a novel extended-release 
capsule formulation of tramadol with once-daily dosing, has Therapeutics and Clinical Risk Management 2007:3(5) 822
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been accepted for review by the US Food and Drug Admin-
istration (FDA) (Cipherpharma 2006).
Finally, a new once-daily abuse deterrent formulation 
of tramadol is being developed by TheraQuest Biosciences 
for the treatment of neuropathic pain. Comparing to CR 
Oxicodone, this TQ-1017 (TheraQuest’s Tramadol ER) 
demonstrates more robust in vitro abuse deterrent properties. 
It represents a secure-release formulation because it cannot 
be easily crushed. Intentional (to obtain rapid euphoria) or 
inadvertent crushing has the potential to deliver a massive 
dose all at once and produce neurological toxicity, including 
agitation, seizures, coma and respiratory failure. The active 
tramadol is also difﬁ  cult to be extracted using common sol-
vents, including alcohol. TQ-1017 has recently completed a 
Phase I study, and is going to be investigated for the man-
agement of post-herpetic neuralgia and for the treatment of 
painful HIV-associated neuropathy (TheraQuest 2006).
Pharmacokinetics of once-daily 
tramadol
The pharmacokinetics of these new once-daily tramadol 
formulations have been investigated in three recent studies, 
by comparison with immediate-release and sustained release 
tramadol products.
In the ﬁ  rst study, an hydrophobic once-daily tramadol 
formulation of in tablets 200 mg (Napp Pharmaceuticals, 
UK) was compared with the immediate-release (IR) trama-
dol solution 100 mg, in a single dose study. The systemic 
availability of OD tablets resulted comparable (94%) to 
that of IR solution. In the six days study, when comparing 
Once-Daily tramadol tablets 200 mg with immediate-release 
(IR) tramadol tablets 50 mg qid, the systemic availability of 
OD tramadol was found lower (74%) than IR tablets. OD 
tramadol exhibited a lower Cmax (maximum observed plasma 
concentration) and a later Tmax (time required to reach Cmax) 
than IR tablets (Smith et al 1999).
In the second study, an hydrophilic once-daily tramadol 
formulation 200 mg (SMB Technology, Belgium) was 
compared with immediate-release tramadol 50 mg qid. In 
the single dose study conducted on 29 healthy volunteers, 
similarly to the previous study (Smith et al 1999) OD trama-
dol showed a signiﬁ  cantly lower Cmax compared to IR tablets, 
for both (+)-tramadol (300 vs 646 ng/ml) and (–)-tramadol 
(255 vs 580 ng/ml). Both enantiomers showed longer Tmax 
in OD tramadol compared to IR tablets (10 vs 1.3 h). How-
ever, systemic bioavailability of tramadol and its metabolite 
enantiomers was similar for both formulations. The AUCt 
(area under the plasma concentration-time curve) and the 
AUC∞ calculated as (AUCt + Ct/Ke) were comparable. In 
the fasting state and after a fatty meal, pharmacokinetic 
parameters did not exhibit signiﬁ  cant differences, showing 
that food did not modify OD tramadol absorption. Following 
repeated dosing, in the seven days study, there was no sig-
niﬁ  cant difference between the AUC of OD tramadol 200 mg 
and IR tramadol qid. As expected, the Cmax was lower after 
the administration of IR tramadol 50 mg, whereas the Cmin 
(minimum observed plasma concentration) was similar for 
both formulations. The OD tramadol produced signiﬁ  cantly 
longer Tmax and sustained plasma drug concentrations for at 
least 24 h (Malonne et al 2003).
The third pharmacokinetic study, conducted by Bodalia 
et al (2003) on 22 healthy volunteers for six days, compared 
three different formulations of oral tramadol: OD tramadol 
150 mg or 200 mg tablets (Napp Pharmaceuticals, UK) 
and IR tramadol 50 mg capsules every eight hours. The 
pharmacokinetic profile of tramadol and its metabolite 
O-desmethyltramadol (M1) followed similar trends. Their 
AUC24 (area under the plasma concentration-time curve over 
24 hours), Cmax, and Cmin values were signiﬁ  cantly higher for 
the IR capsules compared to the OD tablets. However, as the 
conﬁ  dence intervals of the Frel (relative systemic availability, 
expressed as geometric mean) values were within the limits 
of acceptability for bioequivalence, these three treatments can 
be considered to have equivalent mean systemic availability. 
The mean relative systemic availabilities for the OD tablets 
150 mg and the OD tablets 200 mg versus the IR capsules 
were 89.6 % and 90.5%, respectively.
In conclusion, these new sustained release formulations 
of tramadol have suitable pharmacokinetic characteristics to 
be administered once-a-day as an effective and safe treatment 
for acute and chronic pain.
Only recently, a randomized controlled trial comparing 
two different OD tramadol formulations has been published by 
Hernandez-Lopez et al (2006). This is the ﬁ  rst study that com-
pares the bioavailability of a currently marketed OD tramadol 
formulation 200 mg using an hydrophobic matrix (Zambon, 
Spain) with the new OD tramadol formulation 200 mg using 
the Contramid® technology (Labopharm, Canada), both given 
as a single dose in the fasting state. 24 of 26 subjects were 
evaluable for the pharmacokinetic analysis of racemic tramadol 
and racemic O-demethyltramadol. All pharmacokinetic param-
eters (AUC, Cmax, C24h, and Tmax) were signiﬁ  cantly higher for 
tramadol Contramid® (p  0.0004), whereas the elimination 
half-life (T½) was signiﬁ  cantly shorter (7.4 vs 14.9 h, p = 
0.0001). Following tramadol Contramid® oral administration, Therapeutics and Clinical Risk Management 2007:3(5) 823
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mean plasma concentrations maintained a plateau above 200 
ng/ml for a long duration (12h) from 4 h through 16 h after 
dose, while for the reference formulation the plasma levels 
were maintained for only 2 h, from 4 h through 6 h. Mean 
plasma concentration of tramadol at 24 h were signiﬁ  cantly 
higher after tramadol Contramid® administration (38.9 vs 26.2 
ng/ml p = 0.0001). As the conﬁ  dence intervals fall outside of 
the range of acceptability for bioequivalence, these formula-
tions cannot be considered bioequivalent. OD tramadol using 
Contramid® technology seems to have a better controlled-
release proﬁ  le and can be evaluated to be suprabioavailable. 
Finally, authors compared their results with those obtained 
by Malonne et al (2004) with the hydrophilic once-daily 
tramadol formulation 200 mg (SMB Technology, Belgium). 
When comparing the Tmax, expressed as median (min-max), 
the following values were observed: OD tramadol Contra-
mid® (Labopharm) 9.0 h (2–16), OD tramadol (Zambon) 4.5 
h (2–12), and OD tramadol (SMB Technology) 10 h (6–12) 
(Figure 1). The hydrophilic formulation (SMB Technology) 
showed a lag during which no appreciable drug absorption 
occurs, and the maximum concentration was achieved after 
about 10 hours, followed by a fast elimination process, similar 
to the immediate-release formulations. As shown in Figure 1, 
there was not a plateau in the plasma concentration-time curve. 
Thus the author concluded that this should be considered a 
“delayed-release” formulation, whereas the other two (using 
the hydrophobic matrix and the Contramid® technology, 
respectively from Zambon and Labopharm) showed pharma-
cokinetics characteristics of “controlled-release” formulations 
(Hernandez-Lopez et al 2006).
Efﬁ  cacy of once-daily tramadol
The clinical efﬁ  cacy of once-daily tramadol in treating 
chronic non-cancer pain was ﬁ  rst established in two ran-
domized double-blind clinical trials. These compared the 
once-daily formulation with the immediate-release tramadol 
in the treatment of pain in patients with osteoarthritis (Adler 
et al 2002; Bodalia et al 2003).
The ﬁ  rst of these trials was a multicenter study, with a 
double-blind, double-dummy, parallel design (Adler et al 
2002). 279 adult patients with radiographic evidence of OA 
of the spine, hip, and/or knee were assigned to received either 
OD tramadol (Napp Pharmaceuticals, UK) or IR tramadol, 
according to a 2:1 randomization, so that more data could be 
obtained on the OD formulation. During the ﬁ  rst week, doses 
were adjusted until patients required no more than two doses 
of rescue medication (each dose: Acetaminophen 1000 mg) 
per day. The OD tramadol group received 150–400 mg on 
waking (n = 188), while the IR tramadol group received 
50–100 mg TDS or QDS (n = 91). At the end of the titra-
tion period at the optimal dose level of treatment, patients 
were assessed for 4 weeks. Both treatments were equally 
effective in improving pain control. OD and IR tramadol 
were therapeutically equivalent according to pain intensity 
scores at all assayed time points (morning and evening), both 
at baseline (overall 47 and 51 mm, respectively) and after 
treatment (overall 21 and 22 mm, respectively). The 24 hours 
duration of the OD tramadol was clinically conﬁ  rmed by the 
absence of the “end of dose” effects in the morning scores. 
Similar dropout rates were recorded (OD tramadol 49% vs IR 
tramadol 52%). Most of the withdrawals were due to adverse 
events, with a similar proﬁ  le between the two treatments. 
There was no a statistically signiﬁ  cant difference between 
treatments with respect to the number rescue doses over the 
last 24 hours of the study (overall 0.82 times/day), and the 
proportion of nights woken. Assessment of successful global 
pain management was determined by combining patients’ and 
investigators’ ratings of pain control on a 5 point categorical 
scale (from poor to excellent) for each treatment. These 
values were similar for OD tramadol and IR tramadol (overall 
65% of the patients who completed the study obtained good 
to excellent pain relief), further suggesting therapeutic 
equivalence between these two formulations.
The second trial comparing the efﬁ  cacy of OD tramadol 
with IR tramadol was published in 2003 (Bodalia et al 2003). 
This multicenter, randomized, double-blind, double-dummy, 
crossover trial, evaluated the efﬁ  cacy and tolerability of three 
different medications in patients with moderate pain caused 
by radiographically conﬁ  rmed OA of the spine, hip, and/or 
knee. Tested drugs were OD tramadol (Napp Pharmaceuti-
cals, UK) 150 mg tablets in the morning, OD tramadol 200 
mg tablets in the morning, and IR tramadol 50 mg capsules 
three times every day (in the morning, afternoon, and at 
bedtime). Patients were randomized to one of six treatment 
sequence groups. Patients received the appropriate medica-
tion for ﬁ  ve to eight days, and then were switched to the 
alternative treatments. Paracetamol was allowed as escape 
medication. 134 patients were recruited from 22 participating 
centers. 108 completed all three treatment periods. There 
was not statistically signiﬁ  cant difference in the median 
VAS pain scores in any of the four time points investigated: 
before and after the morning dose (range 33 to 40 mm), 
before the afternoon dose, and at bedtime dose (range 26 to 
31 mm). The use of escape medications was similar for the 
three treatments, both during the washout period (overall 2–3 
doses/day) and during the last ﬁ  ve days of treatment (overall Therapeutics and Clinical Risk Management 2007:3(5) 824
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0.4–0.6 doses/day). Also the number of nights woken was 
similar between treatments. One-third of the patients did 
not wake from pain at all during the last three nights of each 
treatment period. Finally, according to the number of patients 
expressing a preference, there were no signiﬁ  cant differences 
between groups in patients’ treatment preference.
In 2004, Mongin et al (2004) published a randomized, 
double-blind, multicenter study to compare the OD tramadol 
Contramid® formulation (Labopharm) with a twice-daily 
formulation. At the baseline phase, analgesic washout was 
programmed prior to randomization, and baseline evaluations 
were performed. 431 patients with diagnosis of moderate to 
moderately severe osteoarthritis of the knee (according to 
ACR criteria) were randomized. During the titration phase, 
dose escalation by 100 mg every 2nd and 3rd day was con-
ducted until minimum effective or maximum tolerated dose 
was achieved. Once the optimum dose level was established, 
the efﬁ  cacy and safety of medications was evaluated in the 
maintenance phase for 84 days. Most patients (50.9% in 
the OD tramadol arm and 49% in the tramadol twice-daily 
arm) received 200 mg daily as the optimal dose. Similar 
discontinuation rates due to adverse events were recorded 
(OD tramadol 8.8% vs twice-daily tramadol 10.2%). Both 
formulations provided similar analgesia, with a 58% reduc-
tion on the primary efﬁ  cacy parameter (percentage change 
in the WOMAC pain subscale score) at 12 weeks, which is 
comparable with pain relief obtained with other analgesics, 
such as codeine and diclofenac. Similarly, no statistically 
signiﬁ  cant differences were observed for each of the second-
ary endpoints (WOMAC stiffness, physical function, global 
score and VAS 24-hours evaluation). The majority of patients 
(about 83%) and investigators (86%) gave an overall rating 
of the study medication as effective or very effective for 
both formulations.
In 2004, the results of the ﬁ  rst two placebo-controlled 
studies evaluating the efﬁ  cacy of OD tramadol were pub-
lished (Babul et al 2004; Malonne et al 2004).
The ﬁ  rst of these trials was a multicenter, double-blind, 
parallel-group, placebo-controlled study, that enrolled 
patients with osteoarthritis of the hip or knee, according to 
European League Against Rheumatism (EULAR) criteria, 
with symptomatology for  6 months, requiring regular 
analgesic treatment for  1 month. Patients were eligible 
for this study if they had pain scores 35 mm on the 100 
mm Huskisson horizontal VAS (0 mm = no pain, 100 mm 
= worst possible pain), and functional discomfort 4 on the 
Lequesne discomfort index (total score 0 = no pain, total 
score 20 = most intense pain). Patients were randomized to 
receive either OD tramadol (SMB Technology, Belgium) 
200 mg or placebo for 14 days. Acetaminophen was allowed 
as rescue analgesia. Regular assessments were programmed 
at day –7 and days 0, 7, and 14. Of 231 randomized patients, 
Figure 1 Mean plasma concentration-time proﬁ  le for racemic tramadol (sum of both enantiomers) after a single oral dose in the fasting state of three different formula-
tions: OD Tramadol Contramid® 200 mg (Labopharm), OD Tramadol 200 mg (Zambon), and OD Tramadol 200 mg (SMB Technology) (Malonne et al 2003; Hernandez-Lopez 
et al 2006).
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197 completed the study (OD tramadol n = 85; placebo 
n = 112). Patients who received OD tramadol had a lower 
pain intensity scores both on day 7 and day 14 (P = 0.0002 
and P = 0.010 respectively) than control patients. Mean 
decrease in pain intensity was 2.43 cm in the OD tramadol 
group, compared with 1.55 cm in the placebo group. The 
proportion of responders was signiﬁ  cantly higher in the OD 
tramadol group compared with the placebo group (64.7% 
vs 50.0% respectively; P = 0.039). Similarly, the proportion 
of patients who did not require rescue doses was higher in 
the OD tramadol group compared with the placebo group 
(60.0% vs 36.6% respectively; P = 0.001). The onset of 
efﬁ  cacy was also faster for OD tramadol than placebo (3 vs 
6 days, respectively; P  0.001). Functional improvement, 
as measured on Lequesne discomfort index, was statistically 
different between groups only at day 7, however there was 
no difference at day 14. The patients’ global assessment of 
treatment was similar for OD tramadol and placebo based 
on a 7-item verbal scale (from much improved to much 
worse). However OD tramadol was ranked as a “very good” 
or “good” method of pain management by signiﬁ  cantly 
more investigators (61.2% vs 30.4%; P  0.001) compared 
with placebo.
A second placebo-controlled study assessed the efﬁ  cacy 
of OD tramadol (Biovail Technology, USA) in 246 patients 
with radiographically conﬁ  rmed OA of the knee and pain 
scores 40 mm (Babul et al 2004). Patients received either 
OD tramadol (n = 124) from 100 mg QD to a maximum of 
400 mg QD, after the ﬁ  rst week, or placebo (n = 122) for 12 
weeks. Clinical evaluations were conducted at Week 1, Week 
2, Week 4, Week 8, and Week 12 or at early termination. In 
the Arthritis Pain Intensity mean change was signiﬁ  cantly 
greater for OD tramadol than placebo (30.4 vs. 17.7 mm; 
P  0.001) Treatment differences emerged into the ﬁ  rst 
week of therapy. Similarly, mean change on the WOMAC 
(Western Ontario and McMaster Universities) pain subscale 
was signiﬁ  cantly greater for OD tramadol over placebo 
(120.1 vs 69.0 mm; P  0.001). Results from all the other 
efﬁ  cacy outcome measures, such as WOMAC Physical 
Function Subscale, WOMAC Stiffness Subscale, and chronic 
Table 1 Efﬁ  cacy of OD tramadol vs other formulation (IR and SR)
Study  Trial design  Patients  Duration and dose   Efﬁ  cacy  Withdrawal
OD Tramadol vs IR Tramadol
Adler et al  Randomized  279 pts.  Titration: 1 week  No signiﬁ  cant differences in:  OD Tram 92 pts (48.9%)
2002  Multicenter  OA spine, hip and/or knee  [from 100 to 400 mg until  VAS pain scores
  Double-blind  Moderate to severe pain  pts required no more than  Use of escape medication (APAP)  IR Tram 47 pts (51.6%)
  Parallel    2 rescue doses (APAP  Sleep quality (number of 
    OD Tram 188pts  500mg) per day]  nights woken)
   (150–400mg)   
    IR Tram 91pts  Study: 1 month  Global assessment of drug
    (50mg or 100mg TDS/QDS)   
Bodalia et al Randomized  134 pts.  5–8 days for each   No signiﬁ  cant differences in:  26 pts
2003  Double-blind  OA spine, hip and/or knee  treatment 
  Cross-over  Moderate to severe pain    VAS pain scores  No signiﬁ  cance differ-
          ences in number of pts.
    3 options:    Use of escape medication (APAP)  withdrawing from each
    OD Tram 150 mg      treatment
    OD Tram 200 mg    Sleep quality 
    IR Tram 50 mg TDS    (number of nights woken)
OD Tramadol vs SR Tramadol twice-daily
Mongin et al Randomized  430 pts.  Titration (every 2nd–3rd  No signiﬁ  cant differences in:  OD Tram 33 pts (15.3%)
2004  Multicenter  OA knee  day by 100 mg until
  Double-blind  Moderate to severe pain  minimum effective,  WOMAC scores
  Parallel    tolerated dose)    SR Tram 37 pts (17.2%)
    OD Tram 215 pts    Patient global assessment
   (100-400  mg)
      Study: 12 weeks  Investigators global assessment
    SR Tram 215 pts  at the ﬁ  xed
    (100–400 mg)  optimum dose  Drop-out ratesTherapeutics and Clinical Risk Management 2007:3(5) 826
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pain sleep inventory (CPSI®), were similar to these main 
ﬁ  ndings, with OD tramadol resulting signiﬁ  cantly superior 
to placebo. Finally, on both the Patient and the Physician 
Global Assessment of Therapy, tramadol was signiﬁ  cantly 
different from placebo.
The results of these two placebo-controlled trials show 
that OD tramadol given at doses of 200 to 400 mg provided 
effective analgesia, when compared to placebo.
The last available study on once-daily tramadol is a 
multicenter, randomized, double-blind, placebo-controlled 
clinical trial that included 1020 adults with osteoarthritis of 
the knee or hip, with baseline pain intensity  40 on a 100 
mm VAS (Gana et al 2006). Patients in the OD tramadol 
active arm were titrated to a target dose of 100, 200, 300, or 
400 mg once daily. Mean changes in WOMAC Osteoarthritis 
Index Pain and Physical Function Subscale were signiﬁ  cantly 
different between OD tramadol and placebo (p ≤ 0.021), and 
for each dose (p ≤ 0.05). OD tramadol resulted more effective 
than placebo also in the other WOMAC items (joint stiffness 
subscale, composite score, pain intensity of the index joint, 
and daily pain intensity score). Global patient assessment of 
disease activity and pain intensity was signiﬁ  cantly better 
for OD tramadol 200 and 300 mg than placebo (p ≤ 0.05). 
Tramadol 400 mg was associated to a higher incidence of 
adverse events.
In conclusion, six RCTs conﬁ  rmed the clinical efﬁ  cacy 
of different OD tramadol formulations in chronic non-cancer 
pain management, in particular in the treatment of moderate 
to severe osteoarthritis (Tables 1 and 2).
Safety and tolerability of once-daily 
tramadol
To date, the safety and tolerability of OD tramadol has been 
examined in a total of 7 published clinical studies (Adler et 
al 2002; Bodalia et al 2003; Babul et al 2004; Malonne et al 
2004, 2005; Mongin et al 2004; Gana et al 2006). As expected 
with an opioid agonist such as tramadol, the 3 most affected 
systems were the gastrointestinal system, central nervous 
system, and peripheral nervous system. Adverse events 
(AEs) associated with OD tramadol included nausea, vomit-
ing, diarrhea, constipation, drowsiness, dizziness, headache, 
somnolence, and pruritus. Nausea and dizziness were the 
Table 2 Efﬁ  cacy of OD tramadol vs placebo
Study  Trial design  Patients  Duration and dose  Efﬁ  cacy  Withdrawal
OD Tramadol vs Placebo
Malonne H.  RCT  197 pts.  2 weeks  OD Tram was signiﬁ  cantly better  OD Tram 24 pts (21.6%)
et al 2004  Placebo-  OA hip or knee    than placebo in:
  controlled        Placebo 2 pts (1.7%)
  Multicenter  OD Tram 85 pts    reducing pain scores
  Double-blind  (200 mg)    mean time to obtain pain
       improvement
    Placebo 112 pts    use of rescue medications
Babul N.  RCT  246 pts.  12 weeks  Change from baseline:  OD Tram 63 pts (50.8%)
et al 2004  Placebo-  OA Knee
 controlled  VAS  40 mm  276 mg/die  Arthritis Pain Intensity (VAS)  Placebo 59 pts (48.4%)
  Double-blind      OD Tram 30.4 mm
    OD Tram 124 pts    Placebo 122 pts
    (100–400 mg)    WOMAC OA Index Pain
        OD Tram 120.1 mm
        Placebo 69 mm
        WOMAC Phys Function Subscale
       OD  Tram  407  mm
        Placebo 208.5 mm
Gana TJ.  RCT  1020 pts.  12 weeks  Signiﬁ  cant differences in:
et al 2006  Placebo-  OA
 controlled  VAS  40 mm    WOMAC OA Index Pain
 Multicenter
  Double-blind  OD Tram    WOMAC (Physical Function Subscale,
    (100–400 mg)    joint stiffness, composite score, 
    Placebo 122    pain intensity of the index joint, and
        daily pain intensity score)
Modiﬁ  ed from Mattia et al (2006).Therapeutics and Clinical Risk Management 2007:3(5) 827
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most common adverse events. Most (91%) of the AEs were 
reported to be mild (Bodalia et al 2003). No serious adverse 
events were reported. No patient treated with OD tramadol 
developed clinical respiratory depression. Tramadol is 
unlikely to produce clinically relevant respiratory depression 
at the recommended dose (Warren et al 2000; Nieuwenhuijs 
et al 2001). We reported a case of iatrogenic respiratory 
depression following tramadol overuse in a patient undergo-
ing haemodialysis treatment (Mattia et al 2004).
The medical examinations and laboratory tests showed 
that OD tramadol had no clinically meaningful effects on 
any laboratory test results, vital signs, physical examination 
ﬁ  ndings, or ECG ﬁ  ndings (Bodalia et al 2003; Babul et al 
2004). Adverse events occurred most often with higher doses 
(400 mg) (Gana et al 2006).
In both the placebo-controlled trials, the overall incidence 
of adverse events was signiﬁ  cantly higher for patients treated 
with OD tramadol compared to those treated with placebo (P 
 0.001) (Babul et al 2004; Malonne et al 2004). Similarly, 
the proportion of patients who dropped out of the study as 
a result of AEs was signiﬁ  cantly higher in the OD tramadol 
group compared to placebo (P  0.001) (Babul et al 2004; 
Malonne et al 2004) However, the frequency and severity 
of AEs with OD tramadol were similar to those observed for 
the immediate- and slow-release formulations. (Adler et al 
2002; Bodalia et al 2003; Mongin et al 2004) The percent-
ages of subjects reporting at least one symptom were similar, 
ranging from 16% to 22%, with the OD tramadol and the IR 
tramadol (Bodalia et al 2003). Obviously, the AE proﬁ  les 
were also similar for the different formulations.
The long-term tolerability open study conducted by 
Malonne et al (2005) on 193 patients with OA and low back 
pain for 12 weeks showed that once-daily tramadol (Labo-
ratoires SMB, Belgium) is safe and well tolerated in most 
of rheumatological patients. The incidence rate of adverse 
events was clearly higher during the ﬁ  rst week (approxi-
mately 19%) than in the following weeks, and decreased 
after the ﬁ  rst month of treatment (between 1 and 5%). This 
conﬁ  rms the long-term tolerability of OD tramadol. Accord-
ing to the results of this open study, the safety proﬁ  le of OD 
tramadol appears extremely more favorable than in the two 
12 weeks RCTs (Babul et al 2004; Mongin et al 2004), as 
shown in Figure 2. One reason for this difference could be 
the more stringent conditions of randomized, controlled, 
double-blind trials (Babul et al 2004; Mongin et al 2004) 
compared to postmarketing surveillance open studies.
However, also in this long-term tolerability open study, 
there is a main limit that could represent the difference 
between the observed study results and current clinical prac-
tice. Despite polipharmacotherapy is the most commonly 
used therapeutic strategy in chronic noncancer pain, 
concomitant treatment with corticosteroids, non-steroidal 
anti-inﬂ  ammatory agents, local anesthetics, centrally acting 
analgesics, neuroleptics, antidepressants, or hypnotics was 
prohibited in this study (Malonne et al 2005). In the clinical 
setting, the risk of drug interaction should be always con-
sidered when using tramadol with certain compounds, in 
particular with serotoninergic medications (additive effect 
on increasing serotonin) leading to an increased possibility 
of serotonin syndrome and seizures, and with other drugs 
Figure 2 Most common adverse events likely related to OD tramadol in 12 weeks double-blind RCTs (Babul et al 2004; Mongin et al 2004).
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which compete for the same liver metabolic pathways 
(CYP2D6 and CYP3A4 of the cytochrome P450 system) 
(Close 2005).
Studies suggested that the incidence of tramadol-induced 
seizures is rare, especially in the therapeutic dosage range, 
and no cases of seizure were recorded in OD tramadol 
clinical studies. However, there has been a recent warn-
ing about the potential risk of seizure when tramadol is 
used in patients with conditions predisposing to seizure 
(diagnoses of epilepsy, malignant brain tumor, stroke, head 
trauma, alcoholism, etc.) or in conjunction with commonly 
prescribed drugs in chronic pain management, such as anti-
convulsants and antidepressants (tricyclic antidepressants 
and serotonin selective reuptake inhibitors) (Gardner et al 
2000; Close 2005).
Conclusion
The efﬁ  cacy and safety proﬁ  le of tramadol make it suitable 
as a long-term treatment in a variety of CNCP conditions. 
OD tramadol formulations show the advantage of smoother 
plasma concentration proﬁ  le, with more gradual absorption 
and lower peak concentrations. Based on results of several 
controlled clinical studies, the efﬁ  cacy of OD tramadol is 
similar to other tramadol formulations for the management 
of chronic non-cancer pain. The OD tramadol allows patients 
to maintain an acceptable level of analgesia following a 
single daily administration, while avoiding peaks in plasma 
concentration and reducing the incidence of adverse events. 
OD tramadol has a clinically favorable adverse events proﬁ  le, 
in particular with regard to reduction of dizziness and vomit-
ing. Furthermore, OD tramadol has the potential to provide 
patients with rheumatological pain optimal analgesic effect, 
with fewer interruptions in sleep, and enhanced physical 
function. Patient satisfaction was demonstrated through the 
high percentage of patients rating therapy with OD tramadol 
as effective or very effective. The OD tramadol formula-
tions could respond to the problem of inconsistent analgesia 
resulting from lack of compliance to treatment with higher 
frequency dosing regimens.
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